Does a History of Non-Vertebral Fracture Identify Women Without Osteoporosis for Treatment?
| Autor: | Kathryn M, Ryder, Steven R, Cummings, Lisa, Palermo, Suzanne, Satterfield, Douglas C, Bauer, Adrianne C, Feldstein, John T, Schousboe, Ann V, Schwartz, Kristine, Ensrud, S R, Cummings |
|---|---|
| Rok vydání: | 2008 |
| Předmět: |
Bone density
Osteoporosis Dentistry Risk Assessment law.invention Placebos Fractures Bone Double-Blind Method Randomized controlled trial Bone Density Risk Factors law Internal Medicine Humans Medicine Osteoporosis Postmenopausal Aged Proportional Hazards Models Aged 80 and over Chi-Square Distribution Alendronate Bone Density Conservation Agents business.industry Proportional hazards model Middle Aged medicine.disease Vertebra Postmenopause medicine.anatomical_structure Fracture (geology) Female Original Article Risk assessment business |
| Zdroj: | Journal of General Internal Medicine. 23:1177-1181 |
| ISSN: | 1525-1497 0884-8734 |
| Popis: | Postmenopausal women with a prior fracture have an increased risk for future fracture. Whether a history of non-vertebral fracture defines a group of women with low bone mass but without osteoporosis for whom alendronate would prevent new non-vertebral fracture is not known.Secondary analysis of data from the Fracture Intervention Trial (FIT). Of 2,785 postmenopausal women with a T-score at the femoral neck between -1 and -2.5 and without prevalent radiographic vertebral deformity, 880 (31.6%) reported experiencing a fracture after 45 years of age. Women were randomized to placebo or alendronate (5 mg/day years for the first 2 years and 10 mg/day thereafter) and were followed for an average of 4.2 +/- 0.5 years. Incident non-vertebral fractures were confirmed by x-rays and radiology reports.In the placebo arm, a self-report of prior fracture identified women with a 1.5-fold (hazard ratio [RH] 1.46, 95% C.I. 1.04-2.04) increased risk for incident non-vertebral fracture. However, there was no evidence that the effect of alendronate differed across subgroups of women with (RH 1.26 for alendronate vs placebo, 95% C.I. 0.89-1.79) and without prior fracture (RH 1.02 for alendronate vs placebo, 95% C.I. 0.76-1.38; P = 0.37 for interaction).Assessing a clinical risk factor, prior non-vertebral fracture, did not identify women with low bone mass for whom alendronate reduced future non-vertebral fracture risk. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink